(Q35601018)

English

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

scientific article published on 13 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study). (English)

1 reference

Europe PubMed Central

9 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

author name string

Jeffrey Kaine

1

1 reference

Europe PubMed Central

9 August 2017

Geoffrey Gladstein

2

1 reference

Europe PubMed Central

9 August 2017

Ingrid Strusberg

3

1 reference

Europe PubMed Central

9 August 2017

Manuel Robles

4

1 reference

Europe PubMed Central

9 August 2017

Ingrid Louw

5

1 reference

Europe PubMed Central

9 August 2017

Sheila Gujrathi

6

1 reference

Europe PubMed Central

9 August 2017

Ramesh Pappu

7

1 reference

Europe PubMed Central

9 August 2017

Ingrid Delaet

8

1 reference

Europe PubMed Central

9 August 2017

Miranda Pans

9

1 reference

Europe PubMed Central

9 August 2017

Charles Ludivico

10

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

13 September 2011

1 reference

Europe PubMed Central

9 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

9 August 2017

71

1 reference

Europe PubMed Central

9 August 2017

1

1 reference

Europe PubMed Central

9 August 2017

38-44

1 reference

Europe PubMed Central

9 August 2017

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

27 July 2018

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

27 July 2018

Factors influencing the immunogenicity of therapeutic proteins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

27 July 2018

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

26 September 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

26 September 2018

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

26 September 2018

The International Conference on Harmonization Good Clinical Practice guideline.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

26 September 2018

Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3233696

26 September 2018

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity, efficacy and adverse events of adalimumab in RA patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on e

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21917824

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2011-200344

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35601018&oldid=1524891358"